Human PV Peripheral Blood Mononuclear Cells (Relapsed/Refractory)

Description

Human PV Peripheral Blood Mononuclear Cells (PV PBMCs) (Relapsed/Refractory) are primary cells isolated from PV patients who have developed resistance to standard therapies (hydroxyurea, interferon-alpha, or JAK2 inhibitors), providing a critical model for studying disease progression and treatment failure in myeloproliferative neoplasms. These PBMCs consist of T cells, B cells, NK cells, and monocytes, exhibiting characteristic small, round morphology and suspension growth. These cells mediate critical immune functions including antigen presentation (monocytes), antibody production (B cells), and cytotoxic responses (Tcells/NK cells). PV PBMCs contain clonal JAK2V617F-mutant hematopoietic cells with additional acquired mutations (e.g., ASXL1, TET2, or TP53) that drive therapeutic resistance, along with an altered immune microenvironment characterized by dysfunctional T/NK cells and pro-inflammatory cytokine production. In advanced translational studies, these samples enable characterization of advanced stage PV immune markers, evaluation of relapsed PV treatment options, implementation of refractory PV monitoring, assessment of novel therapies for relapsed PV, and longitudinal analysis of PV disease progression PBMC profiles.